Literature DB >> 8995712

Understanding the nature of renal disease progression.

G Remuzzi1, P Ruggenenti, A Benigni.   

Abstract

Animal and human proteinuric glomerulopathies evolve to terminal renal failure by a process leading to progressive parenchymal damage, which appears to be relatively independent of the initial insult. Despite the fact that the mechanism(s) leading to renal disease progression has been only partially clarified, several studies have found that the amount of urinary proteins (taken to reflect the degree of protein trafficking through the glomerular capillary) correlated with the tendency of a given disease to progress more than the underlying renal pathology. On the other hand, dietary protein restriction and ACE inhibitors were capable of limiting the progressive decline in GFR to the extent that they could effectively lower the urinary protein excretion rate. A constant feature of proteinuric nephritis is also the concomitant presence of tubulointerstitial inflammation. So far it was not clear if this is a reaction to the ischemic obliteration of peritubular capillaries that follows glomerular obsolescence or whether albumin and other proteins that accumulated in the urinary space are indeed instrumental for the formation of the interstitial inflammatory reaction. In recent years several studies have convincingly documented that excessive and sustained protein trafficking could have an intrinsic renal toxicity. Here we have reviewed the abundant evidence in the literature that the process of reabsorption of filtered proteins activates the proximal tubular epithelium. Biochemical events associated with tubular cell activation in response to protein stress include up-regulation of inflammatory and vasoactive genes such as MCP-1 and endothelins. The corresponding molecules formed in an excessive amount by renal tubuli are secreted toward the basolateral compartment of the cell and give rise to an inflammatory reaction that in most forms of glomerulonephritis consistently precede renal scarring.

Entities:  

Mesh:

Year:  1997        PMID: 8995712     DOI: 10.1038/ki.1997.2

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  90 in total

1.  Transforming growth factor beta contributes to progressive diabetic nephropathy.

Authors:  W B Reeves; T E Andreoli
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-05       Impact factor: 11.205

Review 2.  Aldosterone as a determinant of cardiovascular and renal dysfunction.

Authors:  M Epstein
Journal:  J R Soc Med       Date:  2001-08       Impact factor: 5.344

Review 3.  Nephrology: 4. Strategies for the care of adults with chronic kidney disease.

Authors:  Caroline Stigant; Lesley Stevens; Adeera Levin
Journal:  CMAJ       Date:  2003-06-10       Impact factor: 8.262

Review 4.  Therapeutic modalities in diabetic nephropathy: standard and emerging approaches.

Authors:  Emaad M Abdel-Rahman; Lawand Saadulla; W Brian Reeves; Alaa S Awad
Journal:  J Gen Intern Med       Date:  2011-10-18       Impact factor: 5.128

Review 5.  Lipids and diabetic nephropathy.

Authors:  Rey F Rosario; Sharma Prabhakar
Journal:  Curr Diab Rep       Date:  2006-12       Impact factor: 4.810

6.  Oral supplement of six selective amino acids arrest progression renal failure in uremic patients.

Authors:  Hippocrates Yatzidis
Journal:  Int Urol Nephrol       Date:  2004       Impact factor: 2.370

Review 7.  Combating chronic renal allograft dysfunction : optimal immunosuppressive regimens.

Authors:  Pierre Merville
Journal:  Drugs       Date:  2005       Impact factor: 9.546

8.  Markers of early progressive renal decline in type 2 diabetes suggest different implications for etiological studies and prognostic tests development.

Authors:  Natalia Nowak; Jan Skupien; Adam M Smiles; Masayuki Yamanouchi; Monika A Niewczas; Andrzej T Galecki; Kevin L Duffin; Matthew D Breyer; Nick Pullen; Joseph V Bonventre; Andrzej S Krolewski
Journal:  Kidney Int       Date:  2018-02-02       Impact factor: 10.612

9.  Efficacy of pentoxifylline for reduction of proteinuria in type II diabetic patients.

Authors:  Farshid Oliaei; Shirin Hushmand; Soraya Khafri; Mahmoud Baradaran
Journal:  Caspian J Intern Med       Date:  2011

10.  Randomized, double-blind, controlled study of losartan in children with proteinuria.

Authors:  Nicholas J A Webb; Chun Lam; Tom Loeys; Shahnaz Shahinfar; Juergen Strehlau; Thomas G Wells; Emanuela Santoro; Denise Manas; Gilbert W Gleim
Journal:  Clin J Am Soc Nephrol       Date:  2010-01-14       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.